File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jamcollsurg.2020.08.081
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Continuous improvement in survival outcomes of hepatocellular carcinoma over 2 decades
Title | Continuous improvement in survival outcomes of hepatocellular carcinoma over 2 decades |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jamcollsurg |
Citation | The American College of Surgeons (ACS) Clinical Congress, Virtual Congress, 3-7 October 2020. In Journal of the American College of Surgeons, 2020, v. 231 n. 4, Suppl. 2, p. e33 How to Cite? |
Abstract | Introduction: To investigate the trend of post-treatment survival outcomes of hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 5258 patients over a 20-year period.
Methods: All HCC patients who were treated in a single-university center from 1997-2016 were included. Patients were divided into two 10-year period: period 1=1997-2006 (n = 2520), period 2=2007-2016(n = 2738).
Results: In period 2, patients were older (59 vs 61, p < 0.001), had more medical comorbidities (39.8% vs 48.4%, p < 0.001) and remained male predominant (80% vs 80.1%, p = 0.552). There were more screen detected HCC (25.5% vs 32.9%, p < 0.001). Overall, patients' liver function at time of diagnosis has improved (MELD 9 vs 8, p < 0.001) and indocyanine green retention at 15mins (14.1% vs 12.5%, p < 0.001). Such improvement was likely related to the wide use of hepatitis B antiviral agent since 2003.
In period 2, more patients underwent surgical treatment [liver transplant: 3.4% vs 5.9%, p < 0.001), resection (28.4% vs 31.1%, p < 0.001)] but the rate of ablation was similar (9.4% vs 10.3%).
The overall survival of all patients have improved with median survival from 14.4 to 21.4 months. There was improvement in survival in patients who underwent liver resection, transarterial chemoembolization, systemic treatment and palliative treatment. Post-liver transplant survivals remained excellent and were similar across the decades(5-year survival 84.7% vs 85.1%, p = 0.837).
Conclusion: A continuous improvement of survival outcomes for HCC patients were observed across most treatment categories (resection, TACE, systemic therapy and palliative care). Post-transplant survival was similar as the selection criteria for HCC was consistent and restrictive. |
Description | Session: Hepatobiliary and Pancreas |
Persistent Identifier | http://hdl.handle.net/10722/287317 |
ISSN | 2023 Impact Factor: 3.8 2023 SCImago Journal Rankings: 1.419 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, CLT | - |
dc.contributor.author | Dai, WC | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2020-09-22T02:59:11Z | - |
dc.date.available | 2020-09-22T02:59:11Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | The American College of Surgeons (ACS) Clinical Congress, Virtual Congress, 3-7 October 2020. In Journal of the American College of Surgeons, 2020, v. 231 n. 4, Suppl. 2, p. e33 | - |
dc.identifier.issn | 1072-7515 | - |
dc.identifier.uri | http://hdl.handle.net/10722/287317 | - |
dc.description | Session: Hepatobiliary and Pancreas | - |
dc.description.abstract | Introduction: To investigate the trend of post-treatment survival outcomes of hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 5258 patients over a 20-year period. Methods: All HCC patients who were treated in a single-university center from 1997-2016 were included. Patients were divided into two 10-year period: period 1=1997-2006 (n = 2520), period 2=2007-2016(n = 2738). Results: In period 2, patients were older (59 vs 61, p < 0.001), had more medical comorbidities (39.8% vs 48.4%, p < 0.001) and remained male predominant (80% vs 80.1%, p = 0.552). There were more screen detected HCC (25.5% vs 32.9%, p < 0.001). Overall, patients' liver function at time of diagnosis has improved (MELD 9 vs 8, p < 0.001) and indocyanine green retention at 15mins (14.1% vs 12.5%, p < 0.001). Such improvement was likely related to the wide use of hepatitis B antiviral agent since 2003. In period 2, more patients underwent surgical treatment [liver transplant: 3.4% vs 5.9%, p < 0.001), resection (28.4% vs 31.1%, p < 0.001)] but the rate of ablation was similar (9.4% vs 10.3%). The overall survival of all patients have improved with median survival from 14.4 to 21.4 months. There was improvement in survival in patients who underwent liver resection, transarterial chemoembolization, systemic treatment and palliative treatment. Post-liver transplant survivals remained excellent and were similar across the decades(5-year survival 84.7% vs 85.1%, p = 0.837). Conclusion: A continuous improvement of survival outcomes for HCC patients were observed across most treatment categories (resection, TACE, systemic therapy and palliative care). Post-transplant survival was similar as the selection criteria for HCC was consistent and restrictive. | - |
dc.language | eng | - |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jamcollsurg | - |
dc.relation.ispartof | Journal of the American College of Surgeons | - |
dc.relation.ispartof | Clinical Congress of the American College of Surgeons | - |
dc.title | Continuous improvement in survival outcomes of hepatocellular carcinoma over 2 decades | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Wong, CLT: wongtcl@hku.hk | - |
dc.identifier.email | Dai, WC: daiwc@HKUCC-COM.hku.hk | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Wong, CLT=rp01679 | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.identifier.authority | Cheung, TT=rp02129 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | abstract | - |
dc.identifier.doi | 10.1016/j.jamcollsurg.2020.08.081 | - |
dc.identifier.hkuros | 314167 | - |
dc.identifier.volume | 231 | - |
dc.identifier.issue | 4, Suppl. 2 | - |
dc.identifier.spage | e33 | - |
dc.identifier.epage | e33 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1072-7515 | - |